As a result, MRTX1719 is able to selectively target the essential PRMT5 protein in MTAP-deleted cancer cells while sparing healthy non-tumor cells. This targeting strategy leverages the abnormally elevated levels of MTA present in MTAP-deleted cancers. MRTX1719 has demonstrated in preclinical studies to be a potent, selective inhibitor of the PRMT5 / methylthioadenosine (MTA) complex. Food and Drug Administration (FDA) to evaluate the Company's synthetic lethal PRMT5 inhibitor, MRTX1719, for the treatment of methylthioadenosine phosphoylase ( MTAP)-deleted cancers. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. SAN DIEGO, CA, USA I NovemI Mirati Therapeutics, Inc.
0 Comments
Leave a Reply. |